United Therapeutics (UTHR +0.1%) says it's received approval to perform a human Phase I study in Australia using Pluristem Therapeutics' (PSTI +1.6%) PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension. United Therapeutics and Pluristem entered into a licensing agreement in 2011 that allows UTHR to develop, market and sell PSTI's PLX-PAD cells.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Wed, 10:40AM)
at Investor's Business Daily (Tue, 6:17PM)
at Investor's Business Daily (Tue, 10:04AM)
at Nasdaq.com (Jan 30, 2015)
at Investor's Business Daily (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs